NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Karyopharm Therapeutics Inc. KPTI
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$146.1M
▲ 0.6% vs FY2024
EPS · FY25
$-17.93
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-134.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 146.1M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 134 cents on every revenue dollar this year.
Per share
USD -17.93
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-62.1%
Net margin-134.2%
Return on assets-143.7%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+6.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−2.4%
+6.2%
+89.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.02B
Shares outstanding, FY2025
Change, 5 years+88.9%
Change, 10 years+288.4%
The share count grew 89% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 108.4M
total assets, end of FY2025
Total assetsUSD 108.4M
EquityUSD -292.9M
CashUSD 60.5M
Current ratio1.12×
Equity funds -270% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.1
0.1
0.1
0.2
0.2
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
Operating income $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.2
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
·
·
EBITDA $B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.2
−0.2
−0.2
·
·
·
·
−0.0
−0.0
−0.0
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.1
−0.1
−0.0
−0.0
·
·
·
Net income $B
−0.2
−0.1
−0.1
−0.2
−0.1
−0.2
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−17.93
−14.00
−18.79
−2.02
−1.65
−2.72
−3.22
−3.14
−2.81
−2.92
−3.32
−2.43
−5.59
−8.95
−10.27
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
−391.3
−171.4
−114.1
−88.4
−60.8
−58.3
−41.9
−53.4
·
·
·
·
Shares out B
0.02
0.01
0.11
0.11
0.08
0.07
0.07
0.06
0.05
0.04
0.04
0.03
0.03
0.00
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
43 of 43
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed